Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, teledermatology did not significantly differ from in-person visits in complete response rates for actinic keratosis treatment, but it showed higher treatment failures and more frequent local reactions.

This study identified significant patient frustration with limited access to treatments for alopecia areata in Germany, exacerbated by the absence of health insurance reimbursement for necessary medications.

This review discusses selumetinib for treating symptomatic, inoperable plexiform neurofibromas in pediatric patients with neurofibromatosis type 1 and reports no new clinical results; it provides guidance for Canadian reimbursement decisions.

This review assessed the clinical and cost-effectiveness of baricitinib, an oral treatment for severe alopecia areata in adults, to inform Canadian reimbursement recommendations, excluding Quebec.

In this study, researchers found that ritlecitinib 50 mg offered a lower cost per responder than baricitinib 2 or 4 mg at both 24 and 52 weeks for treating severe alopecia areata, suggesting potential implications for reimbursement or formulary decisions.